MedPath

Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome

Completed
Conditions
Acute Respiratory Distress Syndrome
Registration Number
NCT00557414
Lead Sponsor
National Taiwan University Hospital
Brief Summary

The purpose of this study is to determine the impact of the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) on etiology and prognosis of acute respiratory distress syndrome (ARDS)

Detailed Description

The triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, is upregulated on phagocytic cells in the presence of bacteria or fungi infection and weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form (sTREM-1) in body fluids. The level and serial change of a serum sTREM-1 from cirtical ill patients has been shown to be a good diagnostic and prognostic indicator of ventilation associated pneumonia (VAP) and severe sepsis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
63
Inclusion Criteria
  • Fulfill clinical diagnosis of ARDS
  • Require mechanical ventilation support
Read More
Exclusion Criteria
  • Pregnant
  • Immunocompromised
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Septic or non-septic etiologyAt enrollment
all cause mortality28 days
Secondary Outcome Measures
NameTimeMethod
IL-1 beta, IL-8, TNF-alphaserial follow up at Day 1, 3, 5, 7, 14
CRP, lactate, WBC count, APACHE II score, LIS, SOFA scoreAt enrollment

Trial Locations

Locations (1)

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath